BioDelivery Sciences International Inc. (NASDAQ:BDSI) price on Friday, February 11, fall -1.62% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.64.
A look at the stock’s price movement, the close in the last trading session was $3.70, moving within a range at $3.58 and $3.725. The beta value (5-Year monthly) was 0.84 while the PE ratio in trailing twelve months stood at 12.13. Turning to its 52-week performance, $4.68 and $2.50 were the 52-week high and 52-week low respectively. Overall, BDSI moved 18.57% over the past month.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
BioDelivery Sciences International Inc.’s market cap currently stands at around $355.66 million, with investors looking forward to this quarter’s earnings report slated for Mar 08, 2022 – Mar 14, 2022. Analysts project the company’s earnings per share (EPS) to be $0.01, which has seen fiscal year 2021 EPS growth forecast to increase to $0.21 and about $0.33 for fiscal year 2022. Per the data, EPS growth is expected to be -12.50% for 2022 and 57.10% for the next financial year.
Analysts have a consensus estimate of $42 million for the company’s revenue for the quarter, with a low and high estimate of $40.36 million and $45.42 million respectively. The average forecast suggests down to a -0.40% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $165.34 million, representing a 5.70% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that BDSI is a 75% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 6 recommend BDSI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 0.49, with BDSI’s current price about 3.73% and 15.24% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 60.75, while 7-day volatility ratio is 3.39% and 4.97% in the 30-day chart. Further, BioDelivery Sciences International Inc. (BDSI) has a beta value of 0.74, and an average true range (ATR) of 0.15. Analysts have given the company’s stock an average 52-week price target of $6.79, forecast between a low of $4.50 and high of $10.00. Looking at the price targets, the low is -23.63% off current price level while to achieve the yearly target high, price needs to move -174.73%. Nonetheless, investors will most likely welcome a -92.31% jump to $7.00 which is the analysts’ median price.
In the market, a comparison of BioDelivery Sciences International Inc. (BDSI) and its peers suggest the former has performed considerably weaker. Data shows BDSI’s intraday price has changed -1.62% in last session and -11.65% over the past year. Comparatively, Johnson & Johnson (JNJ) has moved -1.01% on the day and only 0.68% in the past 12 months. Looking at another peer, we see that Pfizer Inc. (PFE) price has gained 0.36% on the day. However, the stock is 46.26% off its price a year ago. Moreover, MediciNova Inc. (MNOV) is also down -1.63% in trading on the day while keeping a a downtrend of -61.03% over the past year. If we look at the PE ratio, we find that BioDelivery Sciences International Inc.’s ratio stands at 12.13 compared to Johnson & Johnson’s 21.47 and Pfizer Inc.’s 15.30. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -1.90% and -1.43% respectively in the last trading.
If we refocus on BioDelivery Sciences International Inc. (NASDAQ:BDSI), historical trading data shows that trading volumes averaged 0.75 million over the past 10 days and 1.54 million over the past 3 months. The company’s latest data on shares outstanding shows there are 98.70 million shares.
The 2.20% of BioDelivery Sciences International Inc.’s shares are in the hands of company insiders while institutional holders own 70.00% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.01 million on Dec 14, 2021, giving us a short ratio of 1.51. The data shows that as of Dec 14, 2021 short interest in BioDelivery Sciences International Inc. (BDSI) stood at 2.03% of shares outstanding, with shares short rising to 1.69 million registered in Nov 14, 2021. Current price change has pushed the stock 17.42% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BDSI stock continues to rise going into the next quarter.